Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lacombe

Showing results (231-240 of 236) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 236 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumorsF Barlési, C Balleyguier, B Besse, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|April 30, 2003
[Development of a self-administered questionnaire to assess women's satisfaction with maternity care]L Gerbaud, M Mascart, B Belgacem, et al.
Leukemia|June 23, 2006
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotypeV Bardet, L D Costa, C Elie, et al.
Leukemia|December 7, 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaL Willems, N Chapuis, A Puissant, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Leukemia|March 11, 2017
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cellsL Poulain, P Sujobert, F Zylbersztejn, et al.
Pageof 24

Showing results (231-240 of 236) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 236 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumorsF Barlési, C Balleyguier, B Besse, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|April 30, 2003
[Development of a self-administered questionnaire to assess women's satisfaction with maternity care]L Gerbaud, M Mascart, B Belgacem, et al.
Leukemia|June 23, 2006
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotypeV Bardet, L D Costa, C Elie, et al.
Leukemia|December 7, 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaL Willems, N Chapuis, A Puissant, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Leukemia|March 11, 2017
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cellsL Poulain, P Sujobert, F Zylbersztejn, et al.
Pageof 24